XTalks

DECEMBER 4, 2024

Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00

Bioavailability 111

Bioavailability Genetic Disease Marketing RNA 111

World of DTC Marketing

JANUARY 24, 2022

To them, a big payday is a small biotech firm being acquired by a big ten pharma company. When they tell small biotech companies to cut costs, there will often be a significant delay in getting the drug to market or massive layoffs of needed staff. Venture capitalists often don’t look that far forward.

Life Science 225

Life Science Drugs Development Genetic Disease 225

pharmaphorum

JANUARY 10, 2022

Not only this, the potential for this type of therapy extends far beyond infectious diseases and into numerous therapy areas. On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. Attracting attention.

RNA 111

RNA Vaccine Vaccination Pharma Companies 111

XTalks

JANUARY 3, 2025

XTALKS WEBINAR: Environmental Sustainability and the Supply of Medicines for Clinical Trials Live and On-Demand: Thursday, January 16, 2025, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn how major pharma companies are working towards environmental sustainability and reducing their environmental impact.

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

DECEMBER 22, 2021

To develop these novel RNA-based therapeutics, we saw a number of big pharma companies team up with smaller biotechs focused on developing RNA-based therapeutics.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

DECEMBER 29, 2022

Vertex is planning to submit a Biologics License Application (BLA) by the end of the first quarter of 2023 and the company says it is also on track to submit exa-cel to UK and European Union (EU) regulators by the end of the year. As such, most gene therapies in late-stage clinical trials are in oncology or rare disease indications.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52